Industry News

Mallinckrodt has entered into an agreement to sell its nuclear imaging business to IBA Molecular for $690 million, the company said Wednesday. The Hazelwood-based drug manufacturer said it is moving away from nuclear imaging to continue its focus on high-growth specialty pharmaceuticals. The deal affects 800 employees and two manufacturing facilities including one in Maryland Heights."/>
Mallinckrodt to sell nuclear imaging business [St. Louis Post-Dispatch]
Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, chairman and CEO, and Sean Whelan, CFO, will present at four upcoming investor conferences. Robert W. Baird 2016 Healthcare Conference in New York on Wednesday, Sept. 7, 2016, at 10:50 a.m. ET Wells Fargo 2016 Healthcare Conference in Boston on Thursday, Sept. 8, 2016, at 10:30 a.m. ET Morgan Stanley Global Healthcare Conference in New..."/>
Diplomat to Participate in Upcoming Investor Conferences
Acerus Pharmaceuticals Corporation, at the request of the Investment Industry Regulatory Organization of Canada on behalf of the Toronto Stock Exchange, announces that it is not aware of any reason for the increase in the Company's share price in today's trading session. The Company is not aware of any material undisclosed corporate developments and has no material change to report at this time. Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical..."/>
Acerus Comments on Trading Activity
Teladoc, Inc., the first and largest telehealth platform in the United States, today announced that Jason Gorevic, chief executive officer, and Mark Hirschhorn, executive vice president and chief financial officer will participate in two upcoming investor conferences. Hirschhorn are scheduled to present at the Wells Fargo 2016 Healthcare Conference in Boston on Wednesday, September 7, 2016 at 2:55 p.m. EDT. Hirschhorn are also scheduled to present at the..."/>
Teladoc to participate in upcoming investor conferences
Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate and for localized prostate cancer. The aim of the study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received..."/>
Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
Cigna and the Cigna Foundation are taking steps to help individuals and communities improve advanced care for the critically ill, and to offer stronger support to family caregivers in Baltimore, Washington, D.C. and Richmond, Va. The Cigna Foundation is providing a two-year $320,000 World of Difference..."/>
Cigna Foundation and Cigna Help Improve Advanced Care for Communities, Customers
Diversity of the Legal and Medical Marijuana Markets
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, today announced the effectiveness of a one-for-twelve reverse stock split of its common stock. The reverse stock split will take effect at 5:00 pm Eastern Time on August 24, 2016 and the Company’ s common stock will open for trading on The NASDAQ Global Select Market on August 25, 2016 on a post-split basis.. The reverse stock split is..."/>
Alphatec Holdings Announces One-for-Twelve Reverse Stock Split
Mallinckrodt has entered into an agreement to sell its nuclear imaging business to IBA Molecular for $690 million, the company said Wednesday. The Hazelwood-based drug manufacturer said it is moving away from nuclear imaging to continue its focus on high-growth specialty pharmaceuticals. The deal affects 800 employees and two manufacturing facilities including one in Maryland Heights."/>
BRIEF: Mallinckrodt to sell nuclear imaging business [St. Louis Post-Dispatch]
Halyard Health, Inc. and Kimberly-Clark Corporation on behalf of investors who purchased or otherwise acquired Kimberly-Clark securities on or after February 25, 2013 and subsequently received Halyard shares pursuant to Kimberly-Clark's spin-off of Halyard, effective as of October 31, 2014; and/or purchased..."/>
GPM Reminds Investors of the August 29th Deadline in the Class Action Lawsuit Against Halyard Health, Inc. and Kimberly-Clark Corporation and Encourages Investors to Contact the Firm
BioMarin Pharmaceutical Inc. announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most Innovative Companies." This is the third consecutive year that BioMarin has received the recognition, acknowledging the company’ s ongoing commitment to rapidly developing and delivering first-in-class or best-in-class therapies for those with severe or life-threatening rare diseases. Last year, the company was also..."/>
Forbes Ranks BioMarin 10th Most Innovative Company in the World
Clovis Oncology stated on Tuesday that its New Drug Application has been accepted by the US Food and Drug Administration for the accelerated approval of rucaparib for the treatment of advanced mutant BRCA ovarian cancer. Following the filing, the US FDA has granted priority review status to the company's application with a Prescription Drug User Fee Act date of 23 February 2017.. Rucaparib was granted Breakthrough Therapy Designation by the US..."/>
Clovis Oncology's NDA for rucaparib accepted by US FDA for accelerated approval for advanced mutant BRCA ovarian cancer
Cotiviti Holdings reported on Tuesday the addition of Ruben J. King-Shaw, Jr., to its board of directors as an independent director. Currently, King-Shaw serves as managing partner and chief investment officer at health care equity firm Mansa Capital LLC, positions he has held since 2011. He is a member of the boards of directors of ODH, NetHealth, Steward Healthcare System, as well as several of Mansa Capital's portfolio companies."/>
Cotiviti names Ruben King-Shaw to board
BioTelemetry disclosed on Tuesday the launch of a strategic foetal health technology partnership with Bloom Technologies. Pursuant to the agreement, Bloomlife will pay BioTelemetry a percentage of revenue to license the latter's proprietary telemetry technology to commercialise a consumer oriented prenatal health sensor, which will collect and deliver a wide variety of prenatal data to expectant mothers that can be shared with their..."/>
BioTelemetry to grant license to its proprietary technology to Bloom Technologies for prenatal market
Zimmer Biomet Holdings declared on Tuesday a cash dividend of USD0.24 per share for the third quarter of 2016.. This dividend is payable on or about 28 October 2016, to stockholders of record at the close of business as of 23 September 2016.. According to the company, the future declarations of dividends are subject to approval of the board of directors and may be adjusted as business needs or market conditions change."/>
Zimmer Biomet's board authorises USD0.24 per share dividend for Q3 2016
Laboratory Corporation of America Holdings reported on Tuesday the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom. On 9 August 2016, LabCorp and its wholly owned subsidiary Savoy Acquisition Corp commenced a tender offer for all of the outstanding common shares of Sequenom, including the associated preferred stock purchase rights, for..."/>
LabCorp passes antitrust review for acquisition of Sequenom
TG Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for the Company’ s oral, next generation PI3K Delta inhibitor, TGR-1202, for the treatment of patients with chronic lymphocytic leukemia. TGR-1202 is currently being evaluated in the UNITY-CLL Phase 3 Trial for patients with both frontline and previously treated CLL.."/>
TG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Canopy Growth Corporation announced that it has closed its previously announced short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 9,453,000 common shares in the capital of the..."/>
Canopy Growth Corporation completes previously announced bought deal financing, including over-allotment, for $34.5 Million

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary657 Articles
Information Technology639 Articles
Financials529 Articles
Health Care379 Articles
Industrials364 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at